340B Providers Should Report How They Use Drug Savings, House Members Say
This article was originally published in The Pink Sheet Daily
Executive Summary
Energy and Commerce Committee Republican members indicate particular concern with knowing how hospitals use drug discount savings to improve patient care.
You may also be interested in...
Hospital Drug Discount Transparency Bill Faces Heavy ‘Lift’ In Congress
But biopharma industry can help drive reform of 340B discounts by emphasizing how it might improve pricing, Rep. Chris Collins, R-NY, suggests.
340B Needs Legislative Fix For Overspending On Medicare Patients, GAO Says
Drug discount program creates financial incentive for participating hospitals to prescribe more drugs or more expensive drugs reimbursed by Medicare Part B, resulting in 'substantially higher' spending, a GAO report says.
Goodbye ‘340B,’ Hello ‘Outpatient Drug Discount Program’ In House Reform Bill
House Commerce Committee members are drafting legislation to make numerous significant changes to the 340B drug discount program, including the definition of eligible patients, new reporting and auditing requirements for providers and drug manufacturers, rules for contract pharmacies – and a new user-fee program for participating health care providers.